Zostavax Market Report 2026

Zostavax Market Overview

• The Zostavax market growth in the historic period has been driven by aging population demographics, rising incidence of shingles among older adults • Market expansion is supported by shift toward recombinant and next-generation vaccines, increasing healthcare expenditure on preventive care • Growth Driver: Impact Of Healthcare Infrastructure Expansion On Vaccine Accessibility And Uptake • North America was the largest region in 2025.

What Is Covered Under Zostavax Market?

Zostavax is a vaccine developed to prevent shingles, a painful rash caused by the reactivation of the varicella-zoster virus, which also causes chickenpox. It is primarily recommended for adults aged 50 and older to reduce the risk of developing shingles and its associated complications, such as postherpetic neuralgia. The main types of zostavax formulations are recombinant vaccine (shingrix) and live attenuated vaccine (zostavax). A recombinant vaccine is made by using genetic engineering to produce an antigen that triggers an immune response without using a live virus. It is used for shingles prevention and post-herpetic neuralgia and is distributed through hospitals and retail pharmacies.

What Is The Zostavax Market Growth Forecast?

The growth in the forecast period can be attributed to shift toward recombinant and next-generation vaccines, increasing healthcare expenditure on preventive care, rising public awareness of postherpetic neuralgia risks, expansion of adult vaccination coverage, improved distribution infrastructure. Major trends in the forecast period include increasing focus on adult immunization programs, rising awareness of shingles prevention, expansion of vaccine access through retail pharmacies, improved cold chain and storage practices, growing emphasis on preventive healthcare.

Global Zostavax Market Segmentation

1) By Formulation: Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax) 2) By Indication: Shingles Prevention, Post-Herpetic Neuralgia 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

What Are The Drivers Of The Zostavax Market?

The expansion of healthcare infrastructure in developing countries is expected to propel the growth of the zostavax market going forward. Healthcare infrastructure refers to the integrated network of facilities, equipment, personnel, and systems required to deliver effective and efficient healthcare services to a population. The expansion of healthcare infrastructure in developing countries is primarily due to growing investments in healthcare facilities and improved access to medical services. Healthcare infrastructure supports zostavax by providing the necessary facilities, resources, and delivery systems to administer the vaccine to the target population, particularly in clinics, hospitals, and pharmacies. For instance, in May 2023, according to the Department of Health and Social Care, a UK-based government department, the UK government has confirmed that the New Hospital Programme receives over $25.33 billion (£20 billion) in investment, aimed at fulfilling the commitment to build 40 new hospitals in England by 2030. In addition to replacing five RAAC hospitals, the program includes three mental health hospitals as part of a broader effort to eliminate dormitory accommodation in mental health facilities and promote equality between physical and mental health care. Two hospitals have already been completed, five are under construction, and over 20 are set to be underway or completed by the end of next year. Therefore, the expansion of healthcare infrastructure in developing countries is driving the growth of the zostavax industry. The surge in the geriatric population is expected to propel the growth of the zostavax market going forward. The geriatric population refers to individuals who are typically aged 65 and older, often requiring specialized medical care due to age-related health issues. The geriatric population is increasing globally due to advancements in healthcare, improved living standards, and better disease management, which have contributed to longer life expectancies. Zostavax is required for the geriatric population because aging weakens the immune system, increasing the risk of developing shingles and its complications, making vaccination essential for prevention. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the surge in the geriatric population is driving the growth of the zostavax industry. The growth in insurance coverage is expected to propel the growth of the zostavax market going forward. Insurance coverage refers to the protection provided by an insurance policy, where the insurer agrees to pay for certain financial losses or medical expenses incurred by the insured, based on the terms and conditions of the policy. Insurance coverage is rising due to increasing awareness of health risks, rising medical costs, and a growing demand for financial protection against unforeseen events and chronic conditions. Zostavax helps insurance coverage by providing a preventative vaccine for shingles, which reduces the risk of costly treatments and long-term healthcare expenses associated with the disease, thereby encouraging insurers to cover its cost as part of proactive health management for eligible individuals, particularly those aged 50 and above. For instance, in June 2024, according to Health Affairs, a US-based nonprofit organization, in 2024, an estimated 92.3% of the U.S. population about 316 million people have health coverage, while 7.7%, or roughly 26 million individuals, remain uninsured; the uninsured share is projected to edge up over the next decade and stabilize at around 8.9% by 2034. Therefore, the growth in insurance coverage is driving the growth of the zostavax industry.

Key Players In The Global Zostavax Market

Major companies operating in the zostavax market are Merck & Co. Inc.

Regional Insights

North America was the largest region in the zostavax market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zostavax Market?

The zostavax market consists of sales of flu vaccines, pneumococcal vaccines hepatitis vaccines and meningitis vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zostavax Market Report 2026?

The zostavax market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zostavax industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.